

Corresponding author(s):	Hirotaka Matsuo
Last updated by author(s):	Dec 6, 2018

Reporting Summary

X Life sciences

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

Statistics					
For all statistical analys	ses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a Confirmed					
☐ ☐ The exact sar	nple size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
A statement	on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
The statistica Only common to	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
A description	of all covariates tested				
A description	of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
AND variation	cion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) in (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
For null hypo Give P values a	thesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted is exact values whenever suitable.				
For Bayesian	analysis, information on the choice of priors and Markov chain Monte Carlo settings				
For hierarchic	cal and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
Estimates of	effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated				
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software and o	code				
Policy information abo	ut <u>availability of computer code</u>				
Data collection	BeadStudio, GenomeStudio v2011 Details about softwares used to collect data have been included in Supplementary Table 2.				
Data analysis	SHAPEIT v1, SHAPEIT v2, minimac, minimac3, mach2qtl v113, EPACTS v3.3, METAL-20110325, LDSC-170205, R v3.5, Popcorn v0.9.9 Details about softwares used to analyze data have been included in the Methods section of our manuscript.				
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.					
Data					
 Accession codes, ur A list of figures that 	ut <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: iique identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability				
We already contacted to the office of National Bioscience Database Center and confirmed that our summary statistics file will be publicly available.					
Field-spec	ific reporting				

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Ecological, evolutionary & environmental sciences

Behavioural & social sciences

ı · c	•			
LITA	sciences	STIIN	$V \cap$	lesign
	301011003	Juan	у	الكالكا

II studies must dis	sclose on these points even when the disclosure is negative.
Sample size	We used existing cohort data. Thus, no sample-size calculation was performed.
Data exclusions	Individuals taking urate-lowering drugs were excluded from the present study. Individuals that didn't pass quality control criteria for the SNP array in each cohort were also excluded from the study. The QC criteria was shown in Supplementary Table 2.
Replication	To replicate our findings, we used publicly available results from Europeans conducted by the Global Urate Genetics Consortium. We downloaded the summary statistics from their website.
Randomization	Our study is an observational study. Thus, no randomization was performed.
Blinding	Our study is an observational study. Thus, no blinding was performed.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		IVIE	ivietilous		
n/a	Involved in the study	n/a	Involved in the study		
\boxtimes	Antibodies	\boxtimes	ChIP-seq		
\boxtimes	Eukaryotic cell lines	\boxtimes	Flow cytometry		
\boxtimes	Palaeontology	\boxtimes	MRI-based neuroimaging		
\boxtimes	Animals and other organisms		•		
	Human research participants				
	Clinical data				
	•				

Human research participants

Policy information about studies involving human research participants

In all cohorts used for our meta-analysis, Japanese subjectes were recruited. Details on the subjects used in this study have been Population characteristics included in the Methods section of our manuscript and Supplementary Table 1. Details on the subjects used in this study have been included in the Methods section of our manuscript and Supplementary Table Recruitment Details about the ethics oversight have been included in the Supplementary Methods. Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about <u>clinical studies</u>

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration	Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.
Study protocol	Note where the full trial protocol can be accessed OR if not available, explain why.
Data collection	Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.
Outcomes	Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.